Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

1.

Breast cancer therapy and cardiovascular risk: focus on trastuzumab.

Sandoo A, Kitas GD, Carmichael AR.

Vasc Health Risk Manag. 2015 Apr 7;11:223-228. eCollection 2015. Review.

2.

Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores.

Dimitroulas T, Hodson J, Sandoo A, Smith J, Kitas GD.

Amino Acids. 2015 Mar 13. [Epub ahead of print]

PMID:
25772817
3.

A methodological approach to non-invasive assessments of vascular function and morphology.

Sandoo A, Kitas GD.

J Vis Exp. 2015 Feb 7;(96). doi: 10.3791/52339.

4.

Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.

Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, Rollefstad S, Ikdahl E, Semb AG, Kitas GD, Van Riel PL, Fransen J.

Ann Rheum Dis. 2015 Feb 17. pii: annrheumdis-2014-206879. doi: 10.1136/annrheumdis-2014-206879. [Epub ahead of print]

PMID:
25691119
5.

Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis.

Dimitroulas T, Sandoo A, Hodson J, Smith J, Panoulas VF, Kitas GD.

Atherosclerosis. 2014 Nov;237(1):38-44. doi: 10.1016/j.atherosclerosis.2014.07.033. Epub 2014 Aug 27.

PMID:
25194333
6.

Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study.

Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD.

Rheumatology (Oxford). 2014 Sep 3. pii: keu349. [Epub ahead of print]

PMID:
25187642
7.

The relationship between cardiovascular disease risk prediction scores and vascular function and morphology in rheumatoid arthritis.

Sandoo A, Chanchlani N, Hodson J, Smith JP, Douglas KM, Kitas GD.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):914-21. Epub 2014 Aug 15.

PMID:
25152090
8.

Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer.

Sandoo A, Kitas GD, Carmichael AR.

Anticancer Res. 2014 Mar;34(3):1147-51. Review.

PMID:
24596352
9.

Asymmetric dimethylarginine is not associated with subendocardial viability ratio in Rheumatoid Arthritis.

Dimitroulas T, Sandoo A, Smith JP, Kitas GD.

Int J Cardiol. 2014 Mar 1;172(1):285-6. doi: 10.1016/j.ijcard.2013.12.235. Epub 2014 Jan 10. No abstract available.

PMID:
24447745
10.
11.

Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden.

Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD.

Rheumatology (Oxford). 2014 Jan;53(1):131-7. doi: 10.1093/rheumatology/ket338. Epub 2013 Oct 3.

PMID:
24097136
12.
13.

Individualised exercise improves endothelial function in patients with rheumatoid arthritis.

Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, Nightingale P, Sandoo A, Dimitroulas T, Kitas GD, Koutedakis Y.

Ann Rheum Dis. 2014 Apr;73(4):748-51. doi: 10.1136/annrheumdis-2013-203291. Epub 2013 Jul 31.

PMID:
23904472
14.

Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance.

Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith JP, Hodson J, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD.

Scand J Rheumatol. 2013;42(3):176-81. doi: 10.3109/03009742.2012.747627. Epub 2013 Jan 14.

PMID:
23311682
15.

Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Dimitroulas T, Sandoo A, Kitas GD.

Int J Mol Sci. 2012 Sep 26;13(10):12315-35. doi: 10.3390/ijms131012315. Review.

16.

The role of inflammation, the autonomic nervous system and classical cardiovascular disease risk factors on subendocardial viability ratio in patients with RA: a cross-sectional and longitudinal study.

Sandoo A, Protogerou AD, Hodson J, Smith JP, Zampeli E, Sfikakis PP, Kitas GD.

Arthritis Res Ther. 2012 Nov 28;14(6):R258. doi: 10.1186/ar4103.

17.

Anti-TNF╬▒ therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study.

Sandoo A, van Zanten JJ, Toms TE, Carroll D, Kitas GD.

BMC Musculoskelet Disord. 2012 Jul 23;13:127. doi: 10.1186/1471-2474-13-127.

18.

Clinical remission following treatment with tumour necrosis factor-alpha antagonists is not accompanied by changes in asymmetric dimethylarginine in patients with rheumatoid arthritis.

Sandoo A, Dimitroulas T, Toms TE, Hodson J, Veldhuijzen van Zanten JJ, Smith JP, Kitas GD.

Clin Biochem. 2012 Nov;45(16-17):1399-403. doi: 10.1016/j.clinbiochem.2012.07.092. Epub 2012 Jul 20.

PMID:
22820438
19.
20.

Lack of association between asymmetric dimethylarginine and in vivo microvascular and macrovascular endothelial function in patients with rheumatoid arthritis.

Sandoo A, Dimitroulas T, Veldhuijzen van Zanten JJ, Smith JP, Metsios GS, Nightingale P, Stavropoulos-Kalinoglou A, Kitas GD.

Clin Exp Rheumatol. 2012 May-Jun;30(3):388-96. Epub 2012 Jun 26.

PMID:
22410121
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk